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Abstract Weight gain remains a well recognized yet difficult
to treat adverse effect of many anti-psychotic drugs including
agents of the first and second generation. The weight gain
liabilities of antipsychotic drugs are partly associated with
their ability to increase appetite.Most behavioral interventions
for weight control remain of limited efficacy, possibly because
they do not specifically target the neuroendocrine factors
regulating appetite. Identifying new weight management
interventions directly acting on the biochemical and neuroen-
docrine mechanisms of anti-psychotic induced weight gain
may help to improve the efficacy of behavioral weight man-
agement programs. Such potentially specific strategies include
(1) using diets which do not increase appetite despite calorie
restriction; (2) countering thirst as an anticholinergic side-
effect; (3) discouraging cannabis use and (4) adding metfor-
min to a behavioral intervention. In view of our currently
rather limited treatment repertoire it seems timely systemati-
cally to explore such novel options.
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Introduction
Weight gain remains a well recognized yet difficult to treat
adverse effect of many anti-psychotic drugs. This problem is
not new. It emerged with the introduction of the first-
generation of antipsychotic drugs (FGAs) but was overshad-
owed by their propensity to cause extrapyramidal side
effects and tardive dyskinesia. Only with the advent of
second-generation antipsychotic drugs (SGAs) the perspec-
tive shifted from movement disorders toward weight gain as
the dominant adverse effect. Weight gain is not just a con-
cern per se. Cosmetically undesirable or even considered
stigmatizing as it may be, the main concern about weight
gain relates to the increased risk of metabolic syndrome,
diabetes and cardiovascular disease which may result in a
significant decrease in life expectancy. For instance, more
than two thirds of people with schizophrenia die from cor-
onary heart disease (CHD) as compared to about half of the
unaffected population [1]. And more than one third of
patients treated with antipsychotic drugs develop metabolic
syndrome [2••]. Depending on age, up to 15% of patients
with schizophrenia may develop type 2- diabetes mellitus
and up to 70% may have elevated serum lipids [2••].
The weight gain liabilities of antipsychotic drugs are
partly associated with their ability to increase appetite. Yet,
most behavioral interventions for weight control do not
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specifically target the control of appetite. Instead, most
interventions are geared toward reduction of calorie intake
through dieting, promotion of fruit and vegetable intake and
calorie expenditure through exercise. However, such strate-
gies tend to increase rather than reduce appetite.
Here we provide an overview of (1) the potential drivers of
antipsychotic-induced increase in appetite and weight gain,
(2) the results of commonly tried behavioral interventions in
view of the underlying pathophysiology, (3) the potential of
behavioral strategies specifically targeted at antipsychotic-
mediated pharmacodynamic and neuroendocrine effects and
4) the role of illicit substance use on appetite.
Potential Drivers of Antipsychotic-Induced Weight Gain
and Increased Appetite
Identifying Receptors Facilitating Weight Gain
Of the FGAs, low-potency phenothiazines such as chlor-
promazine carry the highest risk of increasing weight.
Chlorpromazine may even increase the risk of metabolic
syndrome and type 2- diabetes [3]. On the other hand, the
risk of weight gain is relatively low with high-potency
FGAs such as perphenazine, fluphenazine and haloperidol
[4•, 5]. Of the SGAs, clozapine and olanzapine are most
likely to increase weight, appetite and to stimulate overeat-
ing. Both drugs also increase the risk of metabolic syndrome
and type 2- diabetes. Quetiapine, risperidone, paliperidone,
asenapine, iloperidone and sertindole can also increase
weight but to a lesser extent. These drugs are currently not
associated with an increased risk of metabolic syndrome.
Ziprasidone, amisulpride and aripiprazole and possibly lur-
asidone belong to a third category of antipsychotic drugs in
which the risk of weight gain and appetite increase tends to
be low or negligible [3, 4•, 5, 6].
Blockade of dopamine (D2 and D3), serotonin (5HT2c),
muscarinic (M3) and histamine (H1) receptors have all been
implicated to increase appetite [4•, 5, 7–9]. Weight gain lia-
bility seems inversely correlated to the specificity of the
receptor profile of the antipsychotic drugs; the more receptors
targeted, the less specific the drug and the more likely weight
gain. Thus it is the non-specificity of an individual drug rather
than the categorization into FAGs and SAGs that predict
weight gain liability or metabolic risk [2••]. Nonetheless, even
drugs antagonizing only dopamine receptors (amisulpride,
pimozide, etc.) show at least some propensity for weight gain.
Understanding Determinants of Appetite and Weight Gain
Antipsychotic-induced stimulation of appetite and weight gain
is multifactorial. Pharmacological, genetic, environmental and
social factors as well as gender contribute [2••, 5]. In the
absence of one clearly identifiable factor, identification of a
single effective treatment becomes unlikely. Food intake is the
result of finely balanced neuroendocrine factors. Some of these
promote appetite and others satiety. There are short-acting
factors such as ghrelin and cholecystokinin (CKK). There are
also long acting factors, beyond the time frame of an individual
meal, such as leptin and insulin [4•, 7, 10–18, 19•] (Table 1).
All these factors act on the hypothalamus stimulating either
orexogenic neurons such as neuropeptide-Y (NP-Y) and
agouti-related peptide (AGrP) or anorexic neurons such as
the melanocortins [19•]. Adenosine-monophosphate activated
protein-kinase (AMPK), acts as a cellular energy sensor inte-
grating many of the neuroendocrine functions to become “a
master regulator of eating behavior through its activity in the
hypothalamus” [10]. Hypothalamic activity is under cognitive
and emotional control of the brain though. Whereas the dopa-
mine and endocannabioid system mediate the motivation to
seek food, i.e.m “wanting”, the opioid system mediates feel-
ings of pleasure when eating, i.e., “liking” [15]. Dopamine
antagonists can influence these systems at the hypothalamic
and cortical level, but their actions are not always as might be
anticipated. This makes specific targeting through behavioral
interventions difficult.
For instance, antipsychotics with selective D2 and D3
receptor affinity such as aripiprazole, amisulpride and zipra-
sidone have a low risk of weight gain because blockade of
hypothalamic D2 and D3 receptors increase reactivity to
neuropeptide Y (NPY). This effect may be enhanced by
5HT2 and alpha 1adrenergic blockade [11].
At a cortical level, dopamine and endorphins stimulate
the reward system. Blunting of the reward system by dopa-
mine blockade may lead to overeating in an attempt to
overcome the anhedonic effect [4•, 20]. Genetic variation
may determine how well individual people can suppress
eating [4•]. Thus, individual ability to fine-tune the reward
system may explain why selective D2 and D3 receptor
blockade can cause weight gain in only some people.
Insulin tends to decrease eating behavior under normal
conditions but hyperinsulinemia promotes weight gain [16].
Treatment with insulin is also associated with weight gain.
Hypoglycemia only occurs though if the insulin dose
exceeds carbohydrate intake [21]. The concept that low
blood sugar levels, yet still in the normal range, induce
craving for carbohydrates due to a hyper-secretion of insulin
remains controversial [19•, 22]. Regardless, the individual
response to low-glycemic load diets may differ depending
on ethnicity [23]. Regarding the diabetogenic risk of some
antipsychotics we note that insulin secretion is under mus-
carinic control and blockade of muscarinic (i.e., not nicotin-
ic) receptors may lead to a compensatory over-stimulation
of insulin until it becomes down regulated [24]. Drugs with
anti-muscarinic properties, such as clozapine, olanzapine,
N-desalkylquetiapine are diabetogenic. But olanzapine has
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relatively low rates of anticholinergic adverse effects [25]
and neither demands the use of anticholinergics to counter
extrapyramidal side effects per se. This hypothesis might
also not hold if we adopted the alternative view that insulin
resistance and metabolic syndrome was a consequence of a
disorder of the fat metabolism due to inflammation of adi-
pose tissue rather than a consequence of a dysregulated
carbohydrate metabolism [26].
Table 1 Some factors regulating eating behavior
Substance Organ of origin Mechanism of action
Stimulating food intake
NPY HPT Stimulates neurons triggering eating behavior [7, 10, 11]. Stimulated by ghrelin.
Inhibited by leptin [10, 12].
AgRP HPT Inhibits activity of neurons stimulating melanocortin via GABA. Melanocortin
decrease eating behavior as outlined below [7, 10]. May ↓ thyroid function in
the presence of MSH.
MCH HPT Facilitates action of leptin. ↑ during fasting when leptin levels fall [12].
Projects into the cortex, the amygdala and the spinal cord.
Orexins HPT Regulates feeding behavior and the sleep wake cycle [12]. Ensures food- seeking
behavior after periods of fasting. Projects into the cortex, the amygdala and the
spinal cord [12].
AMPK HPT Intracellular energy sensor acting on ATP concentration. Facilitates production of
ATP by opening catabolic and closing anabolic pathways [10, 13]. If ATP ↑,
AMPK inactive leading ↓ food intake. If ATP ↓, AMPK active leading to ↑ food
intake [10, 13]. AMPK action may differ between cell systems within the HPT and
between tissue types in the body [13, 14]. For instance, the anti-diabetic drug
metformin inhibits AMPK in the HPT but stimulates it in the skeletal muscle [13].
Ghrelin ST Short acting. ↑ eating when the stomach is empty [10]. Stimulates AMPK, NYP and
AgRP and inhibits melanocortin in the HPT [7, 13, 14].
May inhibit insulin release [14]. Falls quickly when food is taken in [10].
Decreasing food intake
Melanocortin producing hormones
including α-MSH and β-MSH.
HPT Block neurons stimulating eating behavior. Counteract NYP and AgRP [7, 10, 12].
Stimulate cholinergic neurons in the spinal cord and thus fine-tune autonomic
regulation of the sympathetic and parasympathetic system [12]. α-MSH is an
agonist for the MC4-R which regulates food intake. Regulates transcription of
thyrotropin-releasing hormone jointly with leptin [12]. MC4-R is a target for the
development of weight-reducing drugs [4•]. Involved in regulating the hypothalamo-
pituitary-adrenal (HPA) axis [12].
BDNF HPT Unclear, may be stimulated by MC4-R in the ventromedial area of the HPT [15].
May interact with leptin and insulin [15].
Insulin PANC Long-acting. Facilitates uptake of glucose in body tissues such as muscles and fat
[10]. Promotes energy expenditure. Inhibits hypothalamic AMPK, NPY and AgRP.
May act synergistically with leptin [10, 16]. Obesity may cause insulin resistance
meaning that less sugar is cleared from the blood. Insulin resistance is a matter of
degree rather than nature [17].
Leptin Mainly AT Long-acting Fat sensor feeding back the amount of triglycerides to the brain by
acting on NPY, AgRP, melanocortin and MSH in the hypothalamus [4•, 10, 12].
If leptin levels ↑ eating ↓. If leptin levels ↓ eating ↑ [10]. Inhibits hypothalamic
AMPK [13, 18]. May act synergistically with insulin [16].
Regulates transcription of thyrotropin-releasing hormone jointly with MSH [12].
Obesity may cause leptin resistance so that eating is not longer reduced when leptin
levels are high [15, 19•].
CKK, GLP-1, YY, PYY3-36, etc. SI Signals a feeling of fullness and satiety [10, 19•]. CKK is short acting. CKK and
GLP-1 may regulate meal size [19•].
Glucagon, amylin, etc. PANC Amylin may regulate meal size together with CKK and GLP-1 [19•].
AT: adipose tissue; AMPK: Adenosinemonophosphate activated protein kinase; AgRP: Agouti-related peptide; BDNF: Brain-derived neurotropic
factor CKK: cholecystokinin; GLP-1: glucagon-like peptide-1; HPT: hypothalamus; MC4-R, melanocortin-4 receptor; MCH: Melanin-
concentrating hormone; - and β-melanocyte stimulating hormone: -MSH and β-MSH; NPY: neuropeptide Y; PYY3-36oxyntomodulinpeptide
YY; PANC: pancreas; SI: Small intestine; ST: stomach
Curr Psychiatry Rep (2013) 15:347 Page 3 of 10, 347
Olanzapine and clozapine in particular are known to
increase leptin [27], but as a rise in leptin is in line with
the fat stores this may be a consequence rather than a cause
of weight gain. High leptin levels decrease appetite but as
body-own leptin targets become reset people finally becom-
ing leptin resistant and continue to overeat despite high
leptin levels. Fasting will then invariably tilt the balance
toward stimulating food intake as an evolutionary bias to-
ward weight gain [15].
The relationship between ghrelin, another potent stimu-
lator of appetite, and SGAs appears more complex; short-
term reductions of ghrelin seem to be followed by longer-
term increases [27]. Finally, SGAs linked to greater weight
gain such as clozapine, olanzapine and quetiapine seem to
stimulate adenosinemonophosphate activated protein kinase
(AMPK) whereas risperidone, ziprasidone, haloperidol and
aripiprazole do not. This AMPK stimulation is linked to H1
blockade [8] making anti-histaminergic properties a prime
risk factor for weight gain.
Behavioral Intervention for Control of Appetite
and Weight Gain – The Evidence
In view of the considerable impact many SGAs and even
some FGAs have on the neuroendocrine system, the ques-
tion arises whether or not behavioral interventions are ef-
fective in preventing or reducing weight gain. The
systematic reviews and meta-analyses reviewed here seem
to support this [28–34] (Table 2). Both, prevention and the
treatment of weight gain, may lead to weight loss of about 3
kg. This corresponds to a reduction of body mass index
(BMI) of approximately one point. In most reviews, preven-
tion led to slightly more weight loss than treatment [28, 29,
31, 32]. A whole array of interventions or combination of
interventions may work, including psychological interven-
tions, diet and exercise. Psychological interventions ranged
from cognitive behavioral therapy (CBT), psycho-
education, motivational interviewing to stress management.
Such interventions were important but it remained unclear
whether CBT or psycho-educational interventions yielded
the better results [28–31]. Outpatient treatment may be
superior to inpatient treatment, but tight calorie restriction
in individual cases of extreme obesity may nevertheless be
best conducted under inpatient conditions [33, 34]. In gen-
eral, it was difficult to unravel the particular contribution of
each treatment component because they tended to overlap.
Programs combining all three, diet, exercise and psycholog-
ical, interventions may work best [29].
Although these results are encouraging it appears that
weight gain associated with to antipsychotic treatment tends
to be greater than weight loss achieved through subsequent
behavioral interventions [35•, 36]. This highlights the
importance of monitoring weight and preventing weight
gain in the first place. Also, significant anti-psychotic in-
duced weight gain tends to occur early in treatment
[35•–37]. Weight may then gradually increase over several
years and only plateau after more than three and a half years
after commencement of antipsychotics [35•, 38, 39]. One
study though, following up 113 patients who received life
style advice in a group setting for 8 years, found that
substantial weight loss could be achieved over long periods
of time. However, this study had no control group and about
70% of the patients had dropped out of the program within
two years [40].
We currently do not know whether weight loss can be
sustained over longer periods of time or if in the end most
patients, like the rest of the population, just re-gain weight or
cycle between weight gain and weight loss [41]. Weight con-
trol measures for people taking antipsychotics are a long-term
commitment to be reconciled with limited health care resour-
ces. At present, it remains unclear whether individual booster
sessions could suffice to maintain the benefit. It follows that
whenever possible, it would be best to opt for an antipsychotic
with low weight gain liabilities rather than to rely on a behav-
ioral intervention to control weight. Once weight gain has
occurred switching to an antipsychotic with less or low weight
gain liabilities also becomes an option [42–45]. Antipsychotic
polypharmacy can also increase the risk [46], but the risk may
depend on the combination chosen [47•].
Behavioral Strategies in Light of Antipsychotic-Mediated
Pharmacodynamic and Neuroendocrine Effects
Behavioral interventions can be used to curtail anti-
psychotic induced weight gain. The evidence for their ef-
fectiveness in daily clinical practice remains limited though,
possibly because current behavioral interventions do not
have specific pharmacodynamic or neuroendocrine treat-
ment targets. Now the question arises as to how we can
augment effectiveness by using interventions specifically
countering mechanisms of weight gain. From our review
of factors regulating appetite, we can identify four such
potential strategies:
1. Using diets which do not increase appetite to reduce
craving for carbohydrates and fat.
2. Countering thirst as an anticholinergic side-effect.
3. Discouraging cannabis use.
4. Adding metformin to a behavioral intervention.
Using Diets Which Do not Increase Appetite
Successful dietary strategies depend on calorie restriction.
Although it makes intuitively sense to reduce calorie intake
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this may turn into an uphill struggle for patients since calorie
restriction invariably leads to increased appetite. Loss of fat
mass will trigger a decrease in leptin. This results in an increase
of appetite in an attempt to restore the fat mass. At the same
time, ghrelin levels inducing appetite may increase [19•]. In
consequence, diets less likely to stimulate appetite despite
energy restriction may lead to better treatment outcomes.
Patients treated with antipsychotics stimulating appetite
and inducing cravings for carbohydrates and fat [48] may
not be able to adhere to calorie restriction. Unless there is
insight into mental illness and the subjective benefits of
antipsychotic treatment are so convincing that they offset
undesirable weight gain, patients are at risk of abandoning
their antipsychotic treatment [49]. Indeed patients receiving
such antipsychotics are faced with a paradox. On the one
hand they are given drugs increasing their appetite. On the
other hand they are told to decrease eating. Hence, diets not
restricting calories and not increasing appetite are the obvi-
ous answer. But such diets are not easy to come by.
Low Carbohydrate High Fat Diet
The prototype of a dietary regimen not restricting calories is
the low carbohydrate-high fat (LCHF), Atkins or ketogenic
Table 2 Effectiveness of behavioral interventions for appetite and weight control – evidence from systematic reviews and meta-analyses during the
last ten years
Study Interventions identified as potentially successful Effect size
Bonfioli E et al. 2012* [28] CBT and psycho-education, diet, exercise. Programs including
all three components highest impact. Similar effects in pts
with first episode or chronic psychosis.
Pooled ES for BMI
T: -0.86; 95% CI: -1.38 to -0.33
P: -1.09; 95% CI: -1.51 to -0.68
TOT: -0.98; 95% CI: -1.31 to -0.65
Caemmerer et al. 2012 [29] Nutritional and/or exercise > CBT, but effectiveness of individual
components difficult to judge since programs tended to overlap.
Effect only seen in out-patient but not in in-patient or mixed trials.
Pooled ES for WGT in kg
T: -3.04; 95% CI: -4.39 to -1.68
P: -3.23; 95% CI: -4.41 to -2.04
Total: -3.12; 95% CI: -4.03 to -2.21
Pooled ES for BMI:
TOT: -0.94; 95% CI: -1.45 to -0.43
Gabriele et al. 2009 [30] T: Diet, exercise and psychological support. Increased length of
intervention may lead to additional weight loss.
ES for WGT in kg
P: Counseling on diet and exercise may decrease the rate of weight
gain but not prevent it all together.
T: mean: -2.63; range: -3.20 to - .40
P: mean: 2.44; range: 0.37 to 4.95
Alvarez-Jiminez et al. 2008 [31] CBT and nutritional counseling, only one study tested a diet and
exercise program. Individual superior to group interventions. No
significant difference between counseling and CBT, prevention
and treatment, pts with recent onset of schizophrenia and chronic
schizophrenia. One trial pointed towards effectiveness of prevention
in pts with recent onset. OP interventions more effective than IP or
mixed sample interventions.
Pooled ES for WGT in kg:
Metformin outperformed behavioral intervention.
T: -2.32; 95% CI: -3.10 to -1.54
Metformin + behavioral intervention outperformed metformin.
P: -3.05; 95%, CI: -4.16 to -1.94
TOT: -2.56; 95% CI: -3.20 to -1.92
Pooled ES for BMI:
TOT: -0.91; 95% CI:-1.13 to -0.68
Faulkner et al. 2007 [32] CBT Pooled ES for WGT in kg:
T: -1.69; 95% CI: -2.77 to -0.61
P: -4.87; 95% CI: -7.11 to -2.64
Pooled effect sizes BMI:
T: -0.66; 95% CI: -1.06 to -0.25
P: -1.52; 95% CI: -2.25 to -0.79
Faulkner et al. 2003 [33] Weight loss difficult but not impossible. Caloric restriction,
reinforcement and adjunct CBT. Caloric restriction may work
best for IP. Exercise could not be evaluated.
Range WGT in kg: -28.57 to 0.4
Werneke et al. 2003 [34] Evidence remains limited. Calorie restriction in an IP setting, but
significant deterioration of mental state can occur. Structured
counseling and CBT. Life-style counseling and reinforcement.
Range (excluding case reports)
WGT in kg: -5.9 to - 0.6, but
results compared with controls
NS in most of the included studies.
CBT: cognitive behavioral therapy; m: month; ES: effect size; IP: inpatients; MA: meta-analysis; P: prevention; OP: outpatients; pt: patient; NS: not
significant; SR: systematic review; T: treatment; TPT: total; WGT: weight; wk: week; y: year
*Provisional version
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diet [50•]. The LCHF diet restricts carbohydrates but freely
allows protein and fat. The LCHF is as effective as conven-
tional diets at reducing weight and improving the lipid
profile by raising “healthy” high-density lipoprotein choles-
terol. Less consistently reported are reductions in blood
sugar and serum triglycerides [51–56]. The LCHF diet
mimics a state of starvation in that it enforces the use of
ketone bodies as the result as the main energy supply.
Essentially, ketone bodies, a result from the break down of
free fatty acids, are used instead of glucose as obtained from
carbohydrate metabolism. As carbohydrates in excess of
100 g per day will prevent ketosis the intake must lie below
this threshold. Commonly, LCHF diets restrict carbohydrate
to 30 g per day. Some extreme approaches only allow 10 g.
Whether the LCHF diet works because of carbohydrate
restriction remains debated. Sacks et al. have shown that
targeting any of the macronutrients may promote weight
loss [57]. As in most Western diets 45-50% of calories stem
from carbohydrates and 35% from fat targeting carbohy-
drates seems more promising. Also, it is now well known
that proteins suppress appetite [58]. Notably, ketone bodies
in their own right may suppress feelings of hunger; this
effect may take about three days to materialize [59]. How-
ever, hunger and appetite may be suppressed right from the
onset of such a diet because the gastro-intestinal peptides can
still signal “fullness” in the absence of calorie restriction.
However, the LHCF diet is highly unpalatable making
long- term compliance difficult. Weight regain appears most
likely when people re-introduce carbohydrates and then end
up on a diet which is both high in fats and carbohydrates
[56], the worst of both worlds [60••]. Excessive protein
intake may carry health risks but the relationship between
such risks and common multifactorial diseases is complex
and hence difficult to assess [61]. Recently, a large cohort
study reported an increase of cardiovascular disease [62•].
The World Health Organization estimates that an intake of
twice the recommended intake may be safe in “physically
active individuals consuming average mixed diets who
would otherwise be identified as having healthy lifestyles”
[61]. Suffice it to say that many patients taking antipsy-
chotics do not fall into this category; their safe upper level
of intake could be lower. Very high protein intakes can also
influence the metabolism and excretion of drugs. Finally,
low carbohydrate intake may adversely affect mood and
increase irritability [63]. This could limit the applicability
of the LCHF in people with severe mental health problems.
Other Options for Cutting Glycemic Load
Possible –non ketogenic- alternative options to cut glycemic
load include the Mediterranean or the glycemic index (GI)
diet. The Mediterranean diet based on a high intake of fiber
and mono-saturated fats such as olive oil, decreases
glycemic load through its higher fats contents [51, 64, 65].
The GI diet reduces intake of foods with a high glycemic
index (foods easily broken down to glucose). Such foods
include refined - white- grain products and products in
which sugar is added during processing or preparation
[66]. Both dietary approaches tilt the balance from pro-
cessed and highly refined to freshly prepared food irrespec-
tive of its carbohydrate and fat content.
The Evidence for Carbohydrate-Reducing Diets
Most people taking antipsychotics will have difficulties
coping with diets requiring a calorie deficit. This provides
a rationale for focusing on diets cutting the glycemic load
especially since carbohydrate provides most of the food
energy. Such specific dietary strategies have however re-
ceived little attention from researchers [67].
The LCHF, the most extreme way to reduce appetite, has
not been tested at all. Clinicians and researchers may believe
that such diets are either too complex to follow or are
detrimental to mental health. Also eating large amounts of
fat to loose weight seems counter-intuitive. In practice
though, most LCHF diets do not contain larger amounts of
fat than normally consumed [55]; the proportion of energy
derived from fat is increased because of the reduced contri-
bution from carbohydrates. Technically, a low-carbohydrate
diet should not pose a greater challenge than a low fat diet or
a calorie restricted diet. Intriguingly, the ketogenic diet has
occasionally been reported to improve psychotic symptoms
in patients suffering from schizophrenia [68, 69]. Given that
the ketogenic diet can be used to treat certain form of
epilepsies such as myoclonic epilepsy [70] and may even
be of value for some patients suffering from autism [71], the
question arises whether this diet could be of some benefit in
other neuro-developmental and degenerative brain disorders
[72] including schizophrenia.
Countering Thirst as an Anticholinergic Side Effect
Some antipsychotics with high weight gain liabilities have
anticholinergic effects. Thus, we can expect dry mouth with
an increased urge to take fluids in compensation to occur.
Notably, clozapine can cause both dry mouth and hypersal-
ivation possibly due to differential effects at adrenergic and
muscarinic receptors [73, 74]. Such effects could lead to
increased salivation during sleep and rest but decreased
salivation during meals [73]. Patients experiencing dry
mouth often increase their fluid intake. At the same time,
they may increase their calorie intake if choosing drinks
containing sugar such as many sodas and fruit juices.
Unsurprisingly, sugar-sweetened sodas are a major con-
tributor to obesity [60••, 75•]. Fruit juices usually get better
press since perceived as rich in vitamins and hence healthy,
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but juices contain a lot of sugar and as a result are quite high
in calories. For example one 300 ml glass of apple juice
contains about 10% sugar providing about 114 kcal, about
the same as three apples [76]. Recent trials have shown that
replacing sugar-sweetened beverages by artificially sweet-
ened drinks can indeed reduce weight gain [77••, 78••].
However, as with so many interventions health benefits
may wane over time [78••].
Milk irrespective of its fat contents has not been
associated with weight gain [60••]. Dairy products have
a role in energy-restricted diets in helping maintaining
nutritional adequacy but have no specific weight reduc-
ing properties [79•]. Reduced fat milk and yoghurt have
fewer calories but most of the nutritional value provided
by full-fat milk. In the UK, dairy intake including milk
has shown to be inversely associated with the consump-
tion of sugar-sweetened drinks in low-income families
[80, 81]. But ultimately fluid intakes are best met by
increased water consumption. In summary, dietary
counseling should include advice on how to drink well
to reduce calorie-intake [56]. There is clearly a need for
a randomized controlled trial in this area.
Discouraging Cannabis Use
Cannabis use is common all over the world and according to
global estimates, 2.8-4.5% of the entire world population
used cannabis at least once in the year 2009 [82]. Cannabis
use is associated with an increased risk of psychotic illness
and conversely, individuals with psychotic illness are more
likely to use cannabis [82] although the estimates vary.
Between, 20 and 50% of all patients with psychotic illness
may consume cannabis and the trend is increasing [82–86].
As the endocannabioid system is linked to increased
appetite and cannabioid receptor antagonists can induce
weight loss [15] cannabis consumption will most likely
potentiate antipsychotic-associated weight gain. As the
prevalence of cannabis use in people suffering from
psychosis is so high, the contribution of cannabis to
weight gain in this population is likely to be significant.
Surprisingly, this link between cannabis and weight gain
remains largely ignored at present. However, one study
of patients admitted to a psychiatric intensive care unit
found that patients using cannabis had higher glucose
levels at admission. They were also significantly more
likely to gain weight during their hospital stay [87], presum-
ably coinciding with the initiation or re-initiation of
antipsychotic treatment.
Adding Metformin to a Behavioral Intervention
Metformin is a bigunanide anti-diabetic drug. Metformin is
also used for the treatment of polycystic ovaries, an endocrine
condition in women leading to testosterone overproduction
linked to insulin resistance. Metformin activates AMPK pe-
ripherally in the liver and there prevents gluconeogenesis [10].
The absence of weight gain implies that metformin does not
act on AMPK centrally in the hypothalamus. Several system-
atic reviews and meta-analyses have been conducted suggest-
ing that metformin can lead to partial reversal of
antipsychotic-associated weight gain and improvement of
the metabolic profile [88••]. However, most trials tended to
be small and of shorter duration. The emerging evidence
suggested that the effect of metformin may be greatest in
younger patients who receive antipsychotics for the first time
and who show a tendency toward rapid weight gain and
metabolic problems [88••, 89]. The most recent trial not yet
included in any systematic review or meta-analysis was con-
ducted in women aged between 18 and 40 years suffering
from a first episode of schizophrenia and antipsychotic-
induced amenorrhea. In this study, metformin was effective
facilitating weight loss, improving insulin resistance and re-
storing menstruation [90•]. However up to date, only one
study evaluated metformin head to head against a behavioral
intervention. All 128 patients in this trial had experienced a
first episode of schizophrenia and gained more than 10%
weight after commencement of drug treatment. In this trial,
metformin was superior to the behavioral intervention, but a
combination of both was superior to metformin alone [91]. In
consequence, early intervention with both behavioral strate-
gies and metformin may well be indicated in people with
mental illness who are about to start anti-psychotic treatment
or who are undergoing treatment and have experienced sig-
nificant weight gain [92, 93].
Conclusion
Behavioral interventions are important for the prevention
and management of antipsychotic-induced weight gain, yet
evidence for their efficacy remains limited. As expected,
interventions to prevent weight gain seem slightly more
effective than strategies to treat weight gain; weight gain,
once it has occurred, is difficult to reverse fully. The results
indicate that whenever possible, antipsychotics associated
with weight gain should be avoided in the first place and
that patients who have experienced weight gain should be
offered a less offending agent. But often, this may not be
feasible when patients have responded well to a particular
agent and the risks and benefits for mental and physical
health have to be weighed up in each individual case.
It should come as no surprise that the scope of successful
behavioral interventions is limited. We find ourselves in the
midst of an obesity epidemic in large parts of the industri-
alized world [75•, 94] and weight interventions such as diet
and exercise have only yielded short rather than long term
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health improvements in the general population without sig-
nificant mental health problems [94]. How much less likely
are people to succeed who experience acute stress or lack of
drive and motivation due to a psychotic illness and who at
the same time require medication increasing their appetite
and weight? We already know that these patients require
long-term psychological support when embarking on weight
control program. Formulating specific strategies directly
acting on the biochemical mechanisms of anti-psychotic
induced weight gain may increase the success of behavioral
programs. In our review we identified four such strategies.
Of these, discouraging consumptions of sugar-sweetened
drinks and cannabis are uncontroversial but continue to lack
systematic study. The argument for adding metformin to a
behavioral intervention is becoming more compelling par-
ticularly in young people. The ketogenic diet is certainly the
most controversial approach discussed in our review. Sur-
prisingly though there is a possibility that this diet may even
yield some mental health benefits and hence be of value in
selected individuals. In view of our currently rather limited
treatment repertoire it seems timely systematically to ex-
plore such more specific, novel and sometimes more ex-
treme options.
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